124 related articles for article (PubMed ID: 36265652)
1. Etomidate elicits anti-tumor capacity by disrupting the JAK2/STAT3 signaling pathway in hepatocellular carcinoma.
Xu J; Zhang L; Li N; Dai J; Zhang R; Yao F; Zhou S; Wu Z; Zhou H; Zhou L; Li Q; Wang X; Liu C
Cancer Lett; 2023 Jan; 552():215970. PubMed ID: 36265652
[TBL] [Abstract][Full Text] [Related]
2. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Zhu M; Shi X; Gong Z; Su Q; Yu R; Wang B; Yang T; Dai B; Zhan Y; Zhang D; Zhang Y
Pharmacol Res; 2020 Aug; 158():104868. PubMed ID: 32407961
[TBL] [Abstract][Full Text] [Related]
3. Targeting C21orf58 is a Novel Treatment Strategy of Hepatocellular Carcinoma by Disrupting the Formation of JAK2/C21orf58/STAT3 Complex.
Jiang H; Wang Y; Wen D; Yu R; Esa SS; Lv K; Feng Q; Liu J; Li F; He L; Di X; Zhang S
Adv Sci (Weinh); 2024 Apr; 11(15):e2306623. PubMed ID: 38342622
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
5. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway.
Zhao H; Guo Y; Li S; Han R; Ying J; Zhu H; Wang Y; Yin L; Han Y; Sun L; Wang Z; Lin Q; Bi X; Jiao Y; Jia H; Zhao J; Huang Z; Li Z; Zhou J; Song W; Meng K; Cai J
Oncotarget; 2015 Oct; 6(31):31927-43. PubMed ID: 26376676
[TBL] [Abstract][Full Text] [Related]
6. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
[TBL] [Abstract][Full Text] [Related]
7. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
Mohan CD; Bharathkumar H; Bulusu KC; Pandey V; Rangappa S; Fuchs JE; Shanmugam MK; Dai X; Li F; Deivasigamani A; Hui KM; Kumar AP; Lobie PE; Bender A; Basappa ; Sethi G; Rangappa KS
J Biol Chem; 2014 Dec; 289(49):34296-307. PubMed ID: 25320076
[TBL] [Abstract][Full Text] [Related]
8. Circ_0072088 promotes progression of hepatocellular carcinoma by activating JAK2/STAT3 signaling pathway via miR-375.
Li L; Xiao C; He K; Xiang G
IUBMB Life; 2021 Sep; 73(9):1153-1165. PubMed ID: 34148288
[TBL] [Abstract][Full Text] [Related]
9. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma.
Gu FM; Li QL; Gao Q; Jiang JH; Zhu K; Huang XY; Pan JF; Yan J; Hu JH; Wang Z; Dai Z; Fan J; Zhou J
Mol Cancer; 2011 Dec; 10():150. PubMed ID: 22171994
[TBL] [Abstract][Full Text] [Related]
10. CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway.
Zhao Z; Song J; Tang B; Fang S; Zhang D; Zheng L; Wu F; Gao Y; Chen C; Hu X; Weng Q; Yang Y; Tu J; Ji J
J Exp Clin Cancer Res; 2020 Nov; 39(1):259. PubMed ID: 33234142
[TBL] [Abstract][Full Text] [Related]
11. Quercetin shows anti-tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway.
Wu L; Li J; Liu T; Li S; Feng J; Yu Q; Zhang J; Chen J; Zhou Y; Ji J; Chen K; Mao Y; Wang F; Dai W; Fan X; Wu J; Guo C
Cancer Med; 2019 Aug; 8(10):4806-4820. PubMed ID: 31273958
[TBL] [Abstract][Full Text] [Related]
12. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
13. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
Liu Y; Liu A; Li H; Li C; Lin J
Cancer Prev Res (Phila); 2011 Aug; 4(8):1296-305. PubMed ID: 21490132
[TBL] [Abstract][Full Text] [Related]
14. LncRNA 00152 promotes the development of hepatocellular carcinoma by activating JAK2/STAT3 pathway.
Li SJ; Sui MH; Sun ZX; Zhang WW
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1038-1046. PubMed ID: 30779070
[TBL] [Abstract][Full Text] [Related]
15. Long Noncoding RNA HOST2 Promotes Epithelial-Mesenchymal Transition, Proliferation, Invasion and Migration of Hepatocellular Carcinoma Cells by Activating the JAK2-STAT3 Signaling Pathway.
Wu Y; Yuan T; Wang WW; Ge PL; Gao ZQ; Zhang G; Tang Z; Dang XW; Zhao YF; Zhang JY; Jiang GZ
Cell Physiol Biochem; 2018; 51(1):301-314. PubMed ID: 30453302
[TBL] [Abstract][Full Text] [Related]
16. Cepharanthine suppresses proliferation and metastasis and enhances apoptosis by regulating JAK2/Stat3 pathway in hepatocellular carcinoma.
Liang Y; Li J; Xu H; Pang M; Hu C; Weng X; Xie W
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):94-100. PubMed ID: 38279472
[TBL] [Abstract][Full Text] [Related]
17. NLRC3 silencing accelerates the invasion of hepatocellular carcinoma cell via IL-6/JAK2/STAT3 pathway activation.
Kang JH; Li MJ; Luan PP; Jiang DK; Chen YW; Xu X; Yu Q; Xu YW; Su Q; Peng WH; Jian WX
Cell Biol Int; 2020 Oct; 44(10):2053-2064. PubMed ID: 32584509
[TBL] [Abstract][Full Text] [Related]
18. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.
Subramaniam A; Shanmugam MK; Ong TH; Li F; Perumal E; Chen L; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Hui KM; Sethi G
Br J Pharmacol; 2013 Oct; 170(4):807-21. PubMed ID: 23848338
[TBL] [Abstract][Full Text] [Related]
19. Amygdalin promotes the activity of T cells to suppress the progression of HBV-related hepatocellular carcinoma via the JAK2/STAT3 signaling pathway.
Wang R; Zhang D; Sun K; Peng J; Zhu W; Yin S; Tang D; Wu Y
BMC Infect Dis; 2021 Jan; 21(1):56. PubMed ID: 33435880
[TBL] [Abstract][Full Text] [Related]
20. MEX3C-Mediated Decay of SOCS3 mRNA Promotes JAK2/STAT3 Signaling to Facilitate Metastasis in Hepatocellular Carcinoma.
Xiao Y; Li Y; Shi D; Wang X; Dai S; Yang M; Kong L; Chen B; Huang X; Lin C; Liao W; Xu B; Chen X; Wang L; Chen X; Ouyang Y; Liu G; Li H; Song L
Cancer Res; 2022 Nov; 82(22):4191-4205. PubMed ID: 36112698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]